GLP-1 and Incretin Peptides: Registered Clinical Trials
Data retrieved November 2, 2026 · Version 1 · Download CSV
Key findings
- 963 unique registered studies matched 3 peptides in this class as of November 2, 2026.
- Semaglutide had the largest number of matching registrations (710).
- Among the last 15 start years, 2026 had the most study starts (226).
- The most frequent lead sponsor was Novo Nordisk A/S (263 studies).
Method
For each peptide in the class, ClinicalTrials.gov (API v2) was searched by intervention name and known aliases. Studies matching more than one peptide are counted once in class-level totals and once per peptide in the per-peptide table.
Retatrutide OR LY3437943— retrieved 2026-11-02Semaglutide OR Ozempic OR Wegovy OR Rybelsus OR NN9535— retrieved 2026-11-02Tirzepatide OR Mounjaro OR Zepbound OR LY3298176— retrieved 2026-11-02
Charts
Data table
| Peptide | Registered studies | Early phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Not applicable |
|---|---|---|---|---|---|---|---|
| Semaglutide | 710 | 6 | 124 | 141 | 178 | 111 | 173 |
| Tirzepatide | 270 | 6 | 37 | 74 | 58 | 45 | 58 |
| Retatrutide | 34 | 0 | 15 | 4 | 14 | 0 | 1 |
Median enrollment by phase (unique studies)
| Phase | Median enrollment |
|---|---|
| Early phase 1 | 24 |
| Not applicable | 140 |
| Phase 1 | 56 |
| Phase 1 / Phase 2 | 98 |
| Phase 2 | 111 |
| Phase 2 / Phase 3 | 55 |
| Phase 3 | 475 |
| Phase 4 | 100 |
Limitations
- Registry data is incomplete: not all studies are registered on ClinicalTrials.gov, and records may be outdated.
- Name and alias searches can miss studies registered under sponsor codes or other names, and can include studies where the peptide is only a comparator.
- Phase and status values are reported by sponsors.
- Start dates for studies not yet started are anticipated dates and may change.
- Counts describe registrations, not results or outcomes.
How to cite this page
EviPep. "GLP-1 and Incretin Peptides: Registered Clinical Trials." 2026. https://evipep.com/research/glp1-class-clinical-trials/ (data retrieved 2026-11-02).
Data may be reused with attribution (CC BY 4.0).
Changelog
- — First version: 963 unique registered studies.